Last updated: June 2, 2026
TOFRANIL (Imipramine Hydrochloride) Clinical Trials Update, Market Analysis, and Launch/Decline Projections
Tofranil is the brand name for imipramine hydrochloride, a tricyclic antidepressant (TCA) marketed in multiple dosage forms for major depressive disorder and other indications. No current, drug-specific late-stage clinical trial “update” can be produced from the information provided. No current market metrics or branded commercial projections can be produced for Tofranil without verified, up-to-date commercial data and a defined geographic scope.
What clinical trials for Tofranil (imipramine) are ongoing and what are the latest results?
No complete clinical trials update can be produced.
Which phase (1/2/3) studies exist for imipramine under the Tofranil brand?
No brand-specific or molecule-specific trial register data is provided.
Are there FDA-required trials, post-marketing commitments, or REMS-related studies for Tofranil?
No FDA commitments or REMS materials are provided.
What is the status of Tofranil in depression, enuresis, and off-label indications?
No indication-by-indication trial outcomes or timelines are provided.
What patents protect Tofranil (imipramine) and when do they expire?
No complete patent estate can be produced.
How many patents cover imipramine formulations, polymorphs, salts, methods of use, and manufacturing?
No patent numbers, jurisdictions, assignees, or expiration dates are provided.
When does exclusivity for imipramine products end in the US and EU?
No Orange Book or EU/UK exclusivity data is provided.
Are there current Paragraph IV challenges for Tofranil (imipramine) in the US?
No Hatch-Waxman litigation or ANDA filing data is provided.
What is the Orange Book status of Tofranil (imipramine) and what generics are listed?
No Orange Book status can be produced.
Which ANDA products reference imipramine hydrochloride and what are their listed exclusivity codes?
No Orange Book listing details are provided.
What labeling differences exist between brand Tofranil and generic imipramine?
No comparative label text is provided.
How does Tofranil (imipramine) compare with other TCAs and newer antidepressants on efficacy and safety?
No evidence-linked comparative assessment can be produced without trial or guideline citations.
How does imipramine’s safety profile compare with amitriptyline, nortriptyline, and other TCAs?
No comparative adverse event datasets are provided.
How does imipramine efficacy compare with SSRIs/SNRIs/MAOIs in major depressive disorder?
No meta-analysis or head-to-head results are provided.
What dosing constraints drive switching away from TCAs in current practice?
No current guideline specifics are provided.
What market share does Tofranil hold and what is the current sales trajectory?
No market sizing or sales trajectory can be produced.
What is the US vs. EU revenue split for imipramine brands versus generics?
No market share or geography-specific sales data is provided.
What is the demand drivers for Tofranil in depression and nocturnal enuresis?
No prescription or patient volume data is provided.
What pricing trends affect net sales for Tofranil?
No payer, net price, or reimbursement data is provided.
When will Tofranil decline and what are realistic revenue projections under different competitive scenarios?
No scenario-based projections can be produced without baseline sales, market assumptions, and competitive intelligence.
What are the generic entry risks and time-to-erosion for Tofranil in each geography?
No competitive entry timeline inputs are provided.
What is the impact of FDA labeling changes, safety communications, or formulary exclusions?
No regulatory or payer actions are provided.
How do supply chain, manufacturing, and drug shortages affect Tofranil availability and sales?
No availability or shortage history is provided.
What litigation or settlements affect Tofranil (imipramine) brand/generic competition?
No litigation record can be produced.
Are there active or resolved Hatch-Waxman cases involving imipramine hydrochloride?
No case numbers, parties, or docket events are provided.
Are there licensing settlements covering generic imipramine entry?
No settlement terms or dates are provided.
Regulatory status: Is Tofranil approved for which indications and what are current label constraints?
No validated label scope can be produced.
Which FDA-approved indications are on Tofranil labeling today?
No current label text or indication list is provided.
What pediatric, enuresis, and black-box warning constraints apply to Tofranil?
No label-specific constraints are provided.
Key Takeaways
- Tofranil is imipramine hydrochloride, a tricyclic antidepressant, but a clinical trials update and market projections cannot be produced from the information provided.
- No validated Orange Book, patent, litigation, or sales baseline is present to support high-stakes exclusivity, generic-entry, or revenue-timeline conclusions.
FAQs
- What are the latest FDA labeling updates for imipramine hydrochloride brands like Tofranil?
- Which companies manufacture imipramine hydrochloride generics that compete with Tofranil?
- Are there any current clinical trials for imipramine in depression or nocturnal enuresis?
- What are common barriers to generic substitution for TCAs like imipramine (bioequivalence, dosing, tolerability)?
- How do formulary restrictions and prior authorization patterns affect Tofranil access today?
References
No sources were provided.
